CASP9

Across TCGA pan-cancer cohorts, CASP9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CASP9 data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CASP9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CASP9 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, CCRCC, and GBM are the cancer types where CASP9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.989	0.768	.001	26	view →
CCRCC	OS	Tertile	III,IV	0.104	0.985	.014	21	view →
GBM	OS	Median	All	0.758	0.953	<.001	15	view →
PDAC	OS	Median	III,IV	0.183	0.930	.010	8	view →
LSCC	OS	Quartile	All	0.666	0.930	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CASP9–HNSC (OS)

Open the HNSC breakdown →